Lucrin

Lucrin is a medication used to treat various conditions, including prostate cancer in men, uterine fibroids, endometriosis, and breast cancer in women, as well as precocious puberty in children. It contains the active ingredient leuprorelin acetate, which helps reduce hormone levels in the body.

Lucrin is available in prefilled dual-chamber syringes, where the active ingredient is a white powder in the front chamber and a colorless solution in the rear chamber. Before use, the liquid and powder must be mixed by a healthcare professional or nurse.

This medication is administered via subcutaneous injection and is designed to provide long-term hormone suppression. It is particularly effective for treating conditions that are hormone-dependent, such as prostate cancer, by reducing testosterone levels to castration levels.

Lucrin is distributed in New Zealand by AbbVie Limited and has been approved for use since October 1991. It is well-established as a treatment for advanced or metastatic prostate cancer and is also used to manage symptoms associated with hormone-sensitive cancers in women.

If you are considering using Lucrin, it is essential to discuss your medical history and any allergies you may have with your doctor. Additionally, Lucrin is not recommended for pregnant or breastfeeding women.

For more detailed information, consult your healthcare provider or the full Consumer Medicine Information (CMI) provided by the manufacturer.